Prolacta Bioscience celebrates Prematurity Awareness Month and World Prematurity Day by recognizing the contributions of breast milk donors, parents of premature infants, and the NICU teams who care for them
Type: Press Releases
Topic(s): 22-27 weeks (extremely premature) Company Donors Growth Long-Term outcomes
New study finds improved long-term neurodevelopmental outcomes for extremely premature infants fed Prolacta’s exclusive human milk diet (EHMD)
Type: Press Releases
Topic(s): Long-Term outcomes Neurodevelopmental Outcomes
Breaking data on the efficacy and cost-effectiveness of an exclusive human milk diet for premature infants to be presented at the American Academy of Pediatrics 2022 National Conference
Type: Press Releases
Topic(s): Company Conferences and Events Cost Savings / Cost Effectiveness
New peer-reviewed study finds vat pasteurization retains molecular structure of naturally occurring bioactive proteins in human donor milk, similar to raw breast milk
Type: Press Releases
Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Microbiome Pasteurization Quality & Safety
Prolacta Bioscience recognizes nurses caring for fragile infants every day throughout Neonatal Nurses Week and NICU Awareness Month
Type: Press Releases
Topic(s): Company
Black, Hispanic, Asian babies born very early are less likely to receive lifesaving measures
Type: Prolacta in the News
Topic(s): 22-27 weeks (extremely premature) Clinical Studies Feeding Protocols Growth Healthcare Professionals
Prolacta Bioscience celebrated Breastfeeding Awareness Month by recognizing the commitment of NICU parents to their infants’ health
Type: Press Releases
Topic(s): Company Parents
Prolacta Bioscience Appoints Dr. Erin Hamilton Spence as Director of Clinical Education and Professional Development
Type: Press Releases
Topic(s): Company
Multiple peer-reviewed studies show Prolacta’s 100% human milk-based nutritional fortifiers reduce risk of life-threatening comorbidities in premature infants, compared to cow milk-based nutrition
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD) Clinical Studies Clinical Studies on Prolact/Humavant CR Company Growth Late-Onset Sepsis Necrotizing Entercolitis (NEC) Retinopathy of Prematurity (ROP)